OxVax ^Companies

OxVax Ltd. is a spin-out company from the University of Oxford that is focused on developing an advanced next-generation dendritic cell vaccine platform for the treatment of solid tumor cancers. Their main goal is to revolutionize cancer treatment by harnessing the power of dendritic cells to stimulate the immune system and target cancer cells specifically. Their achievements include being selected to participate in the Startup Zone of the Advanced Therapies Congress, which is a prestigious event in the field of advanced therapies. OxVax is dedicated to advancing the field of cancer immunotherapy and improving outcomes for patients with solid tumor cancers.